Which has preferable earnings and valuation, STE or BSX?

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.91 $782.30M $8.18 29.08 Boston Scientific $21.00B 3.48 $2.90B $2.47 20.40

Which has better earnings & valuation, DXCM or STE?

DexCom has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 7.47 $836.30M $2.53 36.50 STERIS $5.94B 3.91 $782.30M $8.18 29.08

Is DXCM or STE more profitable?

DexCom has a net margin of 20.12% compared to STERIS's net margin of 13.34%. DexCom's return on equity of 35.94% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% STERIS 13.34% 14.34% 9.66%

STERIS (STE) Competitors

$237.85 +2.11 (+0.90%)

As of 08/21/2026 03:58 PM Eastern

Compare

STE vs. BSX, EW, BDX, IDXX, and DXCM

Should you buy STERIS stock or one of its competitors? STERIS's main competitors and comparable companies include Boston Scientific (BSX), Edwards Lifesciences (EW), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), and DexCom (DXCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does STERIS compare to Boston Scientific?

STERIS (NYSE:STE) and Boston Scientific (NYSE:BSX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

STERIS presently has a consensus price target of $271.33, indicating a potential upside of 14.08%. Boston Scientific has a consensus price target of $71.62, indicating a potential upside of 42.12%. Given Boston Scientific's higher probable upside, analysts plainly believe Boston Scientific is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Boston Scientific	2 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Boston Scientific had 46 more articles in the media than STERIS. MarketBeat recorded 46 mentions for Boston Scientific and 0 mentions for STERIS. Boston Scientific's average media sentiment score of 1.66 beat STERIS's score of 1.21 indicating that Boston Scientific is being referred to more favorably in the news media.

Company	Overall Sentiment
STERIS	Positive
Boston Scientific	Very Positive

Boston Scientific has a net margin of 17.50% compared to STERIS's net margin of 13.34%. Boston Scientific's return on equity of 19.28% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.34%	14.34%	9.66%
Boston Scientific	17.50%	19.28%	10.89%

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.91	$782.30M	$8.18	29.08
Boston Scientific	$21.00B	3.48	$2.90B	$2.47	20.40

94.7% of STERIS shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.3% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

STERIS has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

Boston Scientific beats STERIS on 9 of the 16 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

STERIS has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

In the previous week, Edwards Lifesciences had 28 more articles in the media than STERIS. MarketBeat recorded 28 mentions for Edwards Lifesciences and 0 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 1.56 beat STERIS's score of 1.21 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Overall Sentiment
STERIS	Positive
Edwards Lifesciences	Very Positive

94.7% of STERIS shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.91	$782.30M	$8.18	29.08
Edwards Lifesciences	$6.07B	8.53	$1.07B	$1.74	51.66

Edwards Lifesciences has a net margin of 15.43% compared to STERIS's net margin of 13.34%. Edwards Lifesciences' return on equity of 15.68% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.34%	14.34%	9.66%
Edwards Lifesciences	15.43%	15.68%	12.05%

STERIS presently has a consensus target price of $271.33, suggesting a potential upside of 14.08%. Edwards Lifesciences has a consensus target price of $100.27, suggesting a potential upside of 11.55%. Given STERIS's stronger consensus rating and higher probable upside, analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Edwards Lifesciences	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

Edwards Lifesciences beats STERIS on 10 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Becton, Dickinson and Company has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	2.42	$1.68B	$3.32	57.82
STERIS	$5.94B	3.91	$782.30M	$8.18	29.08

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

STERIS has a net margin of 13.34% compared to Becton, Dickinson and Company's net margin of 4.52%. Becton, Dickinson and Company's return on equity of 14.79% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	4.52%	14.79%	6.93%
STERIS	13.34%	14.34%	9.66%

Becton, Dickinson and Company presently has a consensus target price of $185.67, indicating a potential downside of 3.27%. STERIS has a consensus target price of $271.33, indicating a potential upside of 14.08%. Given STERIS's stronger consensus rating and higher probable upside, analysts plainly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Becton, Dickinson and Company had 34 more articles in the media than STERIS. MarketBeat recorded 34 mentions for Becton, Dickinson and Company and 0 mentions for STERIS. STERIS's average media sentiment score of 1.21 beat Becton, Dickinson and Company's score of 1.20 indicating that STERIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Becton, Dickinson and Company	Positive
STERIS	Positive

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.2%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 30.8% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 53 consecutive years and STERIS has increased its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

STERIS beats Becton, Dickinson and Company on 11 of the 19 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

STERIS (NYSE:STE) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

IDEXX Laboratories has a net margin of 25.03% compared to STERIS's net margin of 13.34%. IDEXX Laboratories' return on equity of 71.96% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.34%	14.34%	9.66%
IDEXX Laboratories	25.03%	71.96%	33.60%

IDEXX Laboratories has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.91	$782.30M	$8.18	29.08
IDEXX Laboratories	$4.30B	10.19	$1.06B	$14.22	39.17

STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

In the previous week, IDEXX Laboratories had 9 more articles in the media than STERIS. MarketBeat recorded 9 mentions for IDEXX Laboratories and 0 mentions for STERIS. STERIS's average media sentiment score of 1.21 beat IDEXX Laboratories' score of 0.98 indicating that STERIS is being referred to more favorably in the media.

Company	Overall Sentiment
STERIS	Positive
IDEXX Laboratories	Positive

STERIS presently has a consensus target price of $271.33, suggesting a potential upside of 14.08%. IDEXX Laboratories has a consensus target price of $747.00, suggesting a potential upside of 34.13%. Given IDEXX Laboratories' higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

IDEXX Laboratories beats STERIS on 11 of the 16 factors compared between the two stocks.

How does STERIS compare to DexCom?

DexCom (NASDAQ:DXCM) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

DexCom currently has a consensus target price of $88.71, indicating a potential downside of 3.93%. STERIS has a consensus target price of $271.33, indicating a potential upside of 14.08%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, DexCom had 23 more articles in the media than STERIS. MarketBeat recorded 23 mentions for DexCom and 0 mentions for STERIS. DexCom's average media sentiment score of 1.65 beat STERIS's score of 1.21 indicating that DexCom is being referred to more favorably in the media.

Company	Overall Sentiment
DexCom	Very Positive
STERIS	Positive

DexCom has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, STERIS has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

DexCom has a net margin of 20.12% compared to STERIS's net margin of 13.34%. DexCom's return on equity of 35.94% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
STERIS	13.34%	14.34%	9.66%

97.8% of DexCom shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DexCom has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50
STERIS	$5.94B	3.91	$782.30M	$8.18	29.08

Summary

DexCom beats STERIS on 13 of the 17 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$23.20B	$6.02B	$7.37B	$24.30B
Dividend Yield	1.06%	1.75%	2.53%	3.70%
P/E Ratio	29.08	26.67	272.60	30.31
Price / Sales	3.91	45.38	618.96	19.89
Price / Cash	15.66	33.24	78.62	32.49
Price / Book	3.21	6.23	13.05	6.77
Net Income	$782.30M	$150.07M	$3.47B	$1.07B
7 Day Performance	2.14%	0.69%	2.09%	-0.65%
1 Month Performance	12.94%	8.91%	6.64%	3.38%
1 Year Performance	-5.51%	8.07%	25.02%	14.90%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.4868 of 5 stars	$237.85 +0.9%	$271.33 +14.1%	-5.5%	$23.20B	$5.94B	29.08	17,937	Positive News
BSX Boston Scientific	4.9566 of 5 stars	$51.46 -0.7%	$71.62 +39.2%	-52.5%	$75.11B	$20.07B	20.83	59,000	Positive News
EW Edwards Lifesciences	4.3187 of 5 stars	$90.84 -0.8%	$100.27 +10.4%	+10.0%	$52.74B	$6.07B	52.21	16,000	News Coverage Positive News
BDX Becton, Dickinson and Company	3.5774 of 5 stars	$182.39 -0.6%	$185.67 +1.8%	-3.8%	$50.53B	$21.84B	54.94	72,000	Positive News
IDXX IDEXX Laboratories	4.6245 of 5 stars	$546.09 -0.9%	$747.00 +36.8%	-13.7%	$43.41B	$4.30B	38.40	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. BSX, EW, BDX, IDXX, and DXCM

How does STERIS compare to Boston Scientific?

Summary

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. BSX, EW, BDX, IDXX, and DXCM

How does STERIS compare to Boston Scientific?

Do analysts rate STE or BSX?

Does the media favor STE or BSX?

Is STE or BSX more profitable?

Which has preferable earnings and valuation, STE or BSX?

Do insiders and institutionals believe in STE or BSX?

Which has more risk and volatility, STE or BSX?

Summary

How does STERIS compare to Edwards Lifesciences?

Which has more volatility and risk, STE or EW?

Does the media favor STE or EW?

Do institutionals and insiders have more ownership in STE or EW?

Which has stronger valuation and earnings, STE or EW?

Is STE or EW more profitable?

Do analysts prefer STE or EW?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Which has more risk and volatility, BDX or STE?

Which has better valuation & earnings, BDX or STE?

Do insiders & institutionals have more ownership in BDX or STE?

Is BDX or STE more profitable?

Do analysts prefer BDX or STE?

Does the media refer more to BDX or STE?

Is BDX or STE a better dividend stock?

Summary

How does STERIS compare to IDEXX Laboratories?

Is STE or IDXX more profitable?

Which has preferable valuation and earnings, STE or IDXX?

Which has more volatility & risk, STE or IDXX?

Does the media favor STE or IDXX?

Do analysts prefer STE or IDXX?

Do institutionals & insiders hold more shares of STE or IDXX?

Summary

How does STERIS compare to DexCom?

Do analysts rate DXCM or STE?

Does the media refer more to DXCM or STE?

Which has more risk & volatility, DXCM or STE?

Is DXCM or STE more profitable?

Do institutionals & insiders have more ownership in DXCM or STE?

Which has better earnings & valuation, DXCM or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools